Exo-peptidase

Exo-Peptidase (Exopeptidase): A Comprehensive Reference

1. Identity: Biochemical Classification, Names, and Forms

1.1 Definition and Nomenclature

An exopeptidase is any peptidase that catalyzes the cleavage of the terminal (or the penultimate) peptide bond; the process releases a single amino acid, dipeptide, or a tripeptide from the peptide chain. The term exo-peptidase (also rendered as exopeptidase, without the hyphen) is the preferred scientific spelling and appears as the U.S. National Library of Medicine Medical Subject Heading (MeSH) term for this enzyme class. The broader term "peptidase" is recommended by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB) for any protein that causes the hydrolysis of peptide bonds; "peptidase" is the most correct scientific term for the proteolytic enzymes that are colloquially called proteases or proteinases.

Peptidases are enzymes that break the peptide bonds linking the amino group of one amino acid with the carboxy group (acid group) of an adjacent amino acid in a peptide chain, and the bonds are broken in a hydrolytic reaction. The two main families of peptidases are exopeptidases and endopeptidases.

1.2 Classification and Enzyme Commission (EC) Numbers

Exopeptidases are a class of proteolytic enzymes that remove amino acids from the termini of peptides and proteins, with two major subclasses being aminopeptidases and carboxypeptidases; they function by cleaving amino acids one at a time or, in some cases, two or three residues at once.

Two sets of sub-subclasses of peptidases are recognised, those of the exopeptidases (EC 3.4.11–19) and those of the endopeptidases (EC 3.4.21–24 and EC 3.4.99). The exopeptidases act only near the ends of polypeptide chains, and those acting at a free N-terminus liberate a single amino-acid residue (aminopeptidases, EC 3.4.11), or a dipeptide or a tripeptide (dipeptidyl-peptidases and tripeptidyl-peptidases, EC 3.4.14).

The full taxonomy of exopeptidase sub-subclasses, as described by the IUBMB, is detailed below:

• Aminopeptidases (EC 3.4.11), dipeptidyl peptidases (EC 3.4.14), and tripeptide peptidases (EC 3.4.14) cleave one, two, or three amino acid residues from the N-terminus, respectively.
• Carboxypeptidases (EC 3.4.12): serine-type (EC 3.4.16), metallocarboxypeptidases (EC 3.4.17), and cysteine-type (EC 3.4.18), which remove one amino acid residue from the C-terminus.
• Dipeptidases (EC 3.4.13) are specific for dipeptides.
• Omega peptidases (EC 3.4.19) remove terminal residues that have neither a free α-amino nor α-carboxyl group.

Depending on whether the amino acid is released from the amino or the carboxy terminal (N-terminus or C-terminus), an exopeptidase is further classified as an aminopeptidase or a carboxypeptidase, respectively. An aminopeptidase, an enzyme in the brush border of the small intestine, will cleave a single amino acid from the amino terminal, whereas carboxypeptidase, which is a digestive enzyme present in pancreatic juice, will cleave a single amino acid from the carboxylic end of the peptide.

1.3 Common Forms and Preparations in Supplements

In the dietary supplement and functional food markets, exo-peptidases are offered in several commercial forms:

• Aminopeptidase (EC 3.4.11) preparations: Exo-Peptidase (Aminopeptidase) 5000 U/g is available as a highly purified, vegan enzyme supplement designed to enhance protein digestion and amino acid absorption in food applications.
• Dipeptidyl peptidase-IV (DPP-IV) preparations, derived from fungal sources such as Aspergillus oryzae, are among the most widely encountered exopeptidase ingredients in commercial enzyme blends targeting gluten and casein digestion.
• Multi-enzyme blends: Products such as ProtectZyme combine Endo-Peptidase Complex and Exo-Peptidase Complex as distinct components within a single capsule formulation.
• Tandem exopeptidase combinations: The investigational formulation AMYNOPEP consists of two tandem-acting aminopeptidases (a monoaminopeptidase and dipeptidyl peptidase) that digest peptides from the amino- to carboxy-terminal to generate absorbable single amino acids and dipeptides.

Exopeptidases are divided into carboxypeptidases or aminopeptidases depending on whether they digest proteins from the carboxy- or amino-terminus, respectively. Proteases are also classified based on their catalytic site architecture, and can be classified into seven broad groups comprising serine proteases, cysteine proteases, threonine proteases, aspartic proteases, glutamic proteases, metalloproteases, and asparagine peptide lyases.

2. Natural Sources

2.1 Endogenous Human Sources

Most exopeptidases of the human gastrointestinal tract are produced by enterocytes at the brush border membrane of the small intestine. Inflammatory damage to the intestinal epithelium in coeliac disease is associated with reduced brush border exopeptidase activity.

The process of digestion of proteins starts in the stomach by pepsins with the help of hydrochloric (HCl) acid. This partially digested protein then reaches the duodenum where a high pH stops the peptic activity, and pancreatic enzymes (trypsin, chymotrypsin, carboxypeptidases) take over the process of digestion. The small chains of amino acids produced in the lumen are now subjected to membrane digestion at the brush border of the enterocytes. The membrane exopeptidases hydrolyze amino acid chains to form individual amino acids that are absorbed into the enterocytes and into the bloodstream to be utilized in the body.

Pancreatic peptidases — specifically endopeptidases trypsin, chymotrypsin and elastase, and exopeptidases carboxypeptidase A and B — digest peptides into smaller fragments.

2.2 Microbial and Fungal Sources (for Supplements)

Exopeptidases are widely distributed in animals, plants, microorganisms, and soil, and can play important roles in both normal biological physiological processes and pathophysiological processes, mainly involving signal transduction, regulation of peptide hormones, protein binding and digestion.

The most studied aminopeptidases are lactic acid bacteria aminopeptidases, and more than 100 kinds of aminopeptidases have been isolated and purified from lactic acid bacteria, but there are relatively few research reports on other microbial exopeptidases related to food fermentation.

From the perspective of industrial enzyme production for supplements and food technology:

• Bacillus species are known to secrete alkaline proteases including serine proteases and neutral metalloproteases; yeasts produce aminopeptidases and carboxypeptidases; and lactic acid bacteria (LAB) release serine protease, zinc metalloprotease and aminopeptidase C.
• Aminogen® is a patented blend of digestive proteases derived from Aspergillus niger and Aspergillus oryzae, which includes exopeptidase activity.
• Accelase is an aminopeptidase from Lactococcus lactis that can be applied to prevent bitterness during cheese ripening. Debitrase is another aminopeptidase from Lactococcus lactis and Aspergillus oryzae that can be used to reduce the bitterness caused by conventional enzymatic hydrolysis.
• Aminopeptidase C (PepC) identified from Lactobacillus paracasei DSM 20258 is a 50.5 kDa exopeptidase that is a cysteine peptidase, hydrolyzing a peptide bond using the thiol-group active site of a cysteine residue.

3. Traditional and Historical Use

Exo-peptidase, as a precisely defined enzyme class, is a product of modern enzymology and biochemistry. It does not appear in traditional herbalism, Ayurveda, Traditional Chinese Medicine (TCM), or other historical medical systems under any equivalent name. Unlike plant-derived enzymes such as bromelain (from pineapple) or papain (from papaya), which have recognizable ethnobotanical histories tied to their source plants, exo-peptidases as isolated or characterized functional enzymes were identified through 20th-century scientific investigation.

Nonetheless, the broader human practice of using proteolytically active foods and fermented products has a relevant indirect history:

• Protein hydrolysis in fermented foods contributes to the flavor profile of fermented foods and increases their nutritional value. This process transforms large protein molecules into smaller peptides and amino acids, making them more easily digestible and absorbable by the human body. Many traditional fermented foods—including cheeses, fermented meats, miso, tempeh, and yogurt—derive a portion of their digestibility benefits from the endogenous exopeptidase activity of fermenting organisms.
• Over the past several decades, there has been a rapid development in the biotechnological use of lactic acid bacteria (LAB) in various branches of the food industry. LAB are a numerous group of microorganisms that have the ability to ferment sugars into lactic acid and to produce proteolytic enzymes. LAB proteolytic enzymes play an important role in supplying cells with the nitrogen compounds necessary for their growth.

The systematic isolation, characterization, and supplemental use of exo-peptidases as defined enzyme ingredients belongs entirely to the modern era, beginning in the latter half of the 20th century and accelerating significantly in the 2010s and 2020s with research into enzyme therapy for gluten-related disorders.

4. Key Constituents / Active Compounds and Mechanisms of Action

4.1 Major Exopeptidase Subclasses Found in Supplements

The term "exo-peptidase" as used on supplement labels is a category descriptor rather than a single molecular entity. Several distinct exopeptidase species are commercially relevant:

• Aminopeptidase N (APN; PepN; EC 3.4.11.2): Exopeptidases referred to as aminopeptidases (EC 3.4.11) have the unique capability of selectively disintegrating polypeptide chains that are initiated at the N-terminus. This enzymatic process results in the liberation of free amino acids, which can then be utilized for various biochemical processes within the organism.
• Dipeptidyl Peptidase-IV (DPP-IV; EC 3.4.14.5): A proline-specific exopeptidase that cleaves dipeptides from the N-terminus of peptides having a proline or alanine in the penultimate position. DPP-IV is particularly relevant to gluten digestion because of the high proline content of immunogenic gluten peptides.
• Carboxypeptidases A and B (EC 3.4.17.1 and 3.4.17.2): Metallocarboxypeptidases present in pancreatic secretion that cleave C-terminal residues.
• Dipeptidyl-peptidases and tripeptidyl-peptidases: These enzymes act at the free N-terminus and release individual residues, dipeptides, or tripeptides (aminopeptidase, dipeptidyl peptidase, and tripeptidyl peptidase, respectively); enzymes that act at the free C-terminus release individual residues (carboxypeptidase) or dipeptides (dipeptidyl carboxypeptidase).

4.2 Catalytic Mechanisms

Serine proteases have a serine in their active site that covalently attaches to one of the protein fragments as an enzymatic intermediate; this class includes the chymotrypsin family (chymotrypsin, trypsin, and elastase) and the subtilisin family. Cysteine proteases have a similar mechanism as serine proteases, but use cysteine rather than serine; they include plant proteases (papain from papaya and bromelain from pineapple) as well as mammalian proteases such as calpains.

With regard to mode of action, endopeptidases cleave intrachain peptide bonds generating peptides of varying lengths. In contrast, exopeptidases sequentially cleave peptide bonds at the amino- or carboxy-terminus ("end-to-end" digestion), generating absorbable fractions (single amino acids, dipeptides or tripeptides).

As an example of enzyme specificity and diversity, aminopeptidase P hydrolyzes N-terminal amino acid from di-, tri- and oligopeptides but only if they are linked to proline, whereas aminopeptidase A catalyzes the hydrolysis of terminal acidic amino acids such as glutamate and aspartate.

4.3 Role in the Digestive Cascade

Endopeptidases initiate the digestion of food proteins, generating new N- and C-termini that are substrates for the exopeptidases that complete the process. This two-stage model is fundamental to understanding why exo-peptidase supplementation is conceptually distinct from, and complementary to, supplementation with endopeptidases alone.

Therapeutic approaches developed to date have almost exclusively focused on stomach-acting endopeptidases (ENPs), a class of enzyme that generates peptides of variable lengths by cleaving intra-chain residues. While ENPs, such as pepsin, trypsin, and chymotrypsin, partially digest peptides into progressively smaller chains, exopeptidases (EXPs) complete digestion by systematically cleaving peptide bonds on either terminal end into absorbable lengths (e.g., single amino acids, dipeptides).

The majority of EXPs are anchored to enterocytes at the brush border membrane (BBM) or released by BBM vesicles into the lumen of the small intestine.

4.4 Structural Regulation of Exopeptidase Activity

To act as an exopeptidase, the peptidase unit (the chymotrypsin fold) must be covered by a regulatory domain to spatially restrict the access of substrate peptides and proteins. Clear examples of an exopeptidase regulatory mechanism have been known for clan SC, family S9 peptidases (e.g., dipeptidyl peptidase IV), in which a catalytic α/β hydrolase fold is covered by a regulatory β-propeller domain.

The process of aminopeptidase hydrolysis is widely utilized in the current food and anti-biofilm sectors due to its numerous advantages, including its high hydrolytic performance, more temperate and mild process conditions that are required, and the fact that the operation is relatively simple and uncomplicated in nature.

5. Scientific Evidence by Area of Use

5.1 Protein Digestion and Amino Acid Absorption (General)

Biological plausibility and in vitro evidence:

Food proteins in the digestive tract undergo the continuous action of various peptidases and are finally broken down into free amino acids. This established physiological role provides a strong biological basis for the hypothesis that exogenous exo-peptidase supplementation might augment this process when endogenous enzymatic capacity is diminished.

Earlier studies have shown that the co-ingestion of an exogenous enzyme blend along with plant protein increases protein digestibility. Previously, several clinical studies have demonstrated a positive impact of enzyme supplementation on protein digestion and absorption.

The use of exo-peptidases to support the digestive system is scientifically justified, as these enzymes play an established role in the final stages of protein breakdown within the human gastrointestinal tract. Scientific studies have demonstrated that supplementation with exogenous proteolytic enzymes, including exo-peptidases, can enhance protein digestion, particularly in individuals with pancreatic insufficiency or certain digestive disorders.

While the biochemical action is well-characterized and there is moderate evidence from clinical studies, the direct health impact in people with normal digestive function is less well established, and some studies have limitations in sample size or design.

Evidence strength: The role of exo-peptidases in the normal digestive physiology of protein is extremely well-established at the biochemical level. Clinical evidence for supplemental exo-peptidase preparations specifically improving measurable amino acid absorption or nutritional outcomes in healthy individuals is limited and, where present, involves multi-enzyme blends rather than pure exo-peptidase preparations in isolation.

5.2 Gluten Peptide Digestion and Celiac Disease / Gluten Sensitivity

This is the area with the most directly targeted and recent human clinical evidence for exo-peptidase supplementation specifically.

Background: Coeliac disease is a common autoimmune-like enteropathy caused by an acquired proinflammatory T cell-mediated immune response to specific peptide fragments derived from certain gluten proteins during digestion. Human gastrointestinal peptidases are slow and inefficient at digesting gluten as they generally lack cleavage activity for proline-adjacent bonds.

Proline residues comprise approximately 14% of amino acids in gluten proteins (glutamine accounts for approximately 32%), but proline is enriched to 30% and 39% in gluten peptides that are immunogenic or immunodominant, respectively, for gluten-specific T cells in coeliac disease.

Endogenous exopeptidase deficiency in celiac disease: Patients with CeD experience damage to the intestinal BBM and reduced activity of certain brush border EXPs. For instance, activity of the endogenous proline-specific dipeptidyl peptidase-IV (DPP-IV) was shown to be reduced by an average of 70% in CeD patients compared to healthy individuals without gastrointestinal diseases, likely aggravating the indigestibility of gluten immunogenic peptides and their accumulation.

Inflammatory damage to the intestinal epithelium in coeliac disease is associated with reduced brush border exopeptidase activity, and this enzyme loss is likely to exacerbate gluten peptide accumulation.

Key human clinical study (2024 — AMYNOPEP crossover trial):

Published in 2024 (DOI: 10.3389/fimmu.2024.1425982), the study was conducted by investigators from AMYRA Biotech AG, University Medicine Greifswald, and the Institute of Pharmacy, University of Greifswald.

The investigational preparation AMYNOPEP is a novel enzyme therapy approach to support gluten peptide digestion using a combination of two tandem-acting exopeptidases that complement the intrinsic enzymatic activity of intestinal brush border enterocytes. The effects of AMYNOPEP supplementation on 33-mer degradation in vitro and in vivo were evaluated.

Study design: In a cross-over clinical study, healthy volunteers with no gastrointestinal disorders were given stable isotope (SI) labelled 33-mer peptides in the presence of varying peptide substrates and caloric loads, with and without AMYNOPEP. 33-mer degradation products (SI-labelled single amino acids) were measured in the blood plasma using LC-MS/MS.

Results: AMYNOPEP achieved rapid, complete amino-to-carboxyl terminal degradation of the 33-mer in vitro, generating single amino acids and dipeptides. In healthy volunteers, AMYNOPEP supplementation significantly increased 33-mer degradation and absorption of SI-labelled amino acids even in the presence of competing substrates. Specifically, a 2.8-fold increase in the Cmax of stable isotope-labelled amino acids in the presence of wheat gluten was observed. The absorption kinetics of labelled amino acids derived from 33-mer digestion with AMYNOPEP closely resembled that of SI-labelled X-Proline dipeptides administered without enzyme supplementation, highlighting the rapid hydrolytic activity of AMYNOPEP on polypeptides.

Conclusions: AMYNOPEP achieved complete degradation of the 33-mer into single amino acids and dipeptides in vitro and significantly improved 33-mer degradation kinetics in healthy volunteers, as measured by labelled amino acid detection, warranting further investigation into the potential therapeutic benefits of exopeptidase combinations for patients with gluten-related health disorders including celiac disease.

Limitations: This study was conducted exclusively in healthy volunteers—not in patients with celiac disease or non-celiac gluten sensitivity. As a next step, further clinical studies are planned to investigate AMYNOPEP's enzyme efficacy, immune response suppression, and symptom relief in patients with celiac disease. Therefore, the evidence for clinical benefit in the target patient population (CeD) remains at the proof-of-concept stage as of the study's publication.

Evidence from single-agent DPP-IV studies and available OTC enzyme supplements:

Studies evaluating available digestive enzyme supplements have shown comparable proteolytic activities with near-neutral pH optima and modest gluten detoxification properties as determined by ELISA. Mass spectrometric analysis revealed the presence of many different enzymes including amylases and a variety of different proteases with aminopeptidase and carboxypeptidase activity. The enzyme supplements leave the nine immunogenic epitopes of the 26-mer and 33-mer gliadin fragments largely intact.

In contrast, the pure enzyme AN-PEP effectively degraded all nine epitopes in the pH range of the stomach at much lower dose. Currently available digestive enzyme supplements are ineffective in degrading immunogenic gluten epitopes.

A study on Aspergillus oryzae exopeptidase DPP-IV and Aspergillus niger endopeptidase PEP (AN-PEP) found that though neither enzyme efficiently cleaved synthetic gluten immunogenic peptides as a single agent, they efficiently digested these peptides when applied in combination in vitro, including in the presence of competitive substrates (casein) and in whole wheat bread.

As single agents, exopeptidases are inefficient as they have limited substrate range, as seen with DPP-IV supplements currently on the market. Developing unique combinations of exopeptidases with complementary and enhanced activity is needed to thoroughly break down proteolytically resistant food peptides.

Evidence strength: For general commercial DPP-IV and exopeptidase supplements marketed for gluten intolerance, the evidence is weak to negative—available OTC products have been shown to be largely ineffective at degrading immunogenic gluten epitopes. For the novel combination approach (tandem exopeptidase therapy), the evidence is preliminary but encouraging: a single well-designed crossover study in healthy volunteers demonstrates proof of concept in humans, but no published controlled trials in celiac disease patients exist as of late 2024.

5.3 Food Bitterness Reduction and Protein Quality in Fermented Foods

Exopeptidases, including aminopeptidases and carboxypeptidases, target the terminal amino or carboxyl ends of proteins, breaking the peptide chains down into smaller peptides or amino acids. Protein hydrolysis not only contributes to the flavor profile of fermented foods but also increases their nutritional value, transforming large protein molecules into smaller peptides and amino acids, making them more easily digestible and absorbable by the human body.

This area of use is well-established in food science and industrial food technology but is not a direct supplement efficacy claim in the context of human health outcomes.

5.4 Signal Transduction and Peptide Hormone Regulation

Exopeptidases can play important roles in both normal biological physiological processes and pathophysiological processes, mainly involving signal transduction, regulation of peptide hormones, protein binding, and digestion. These roles are well-characterized in endogenous physiology but have not been the subject of human clinical trials of exo-peptidase supplementation for these specific purposes.

6. Body Systems and Health Areas

6.1 Gastrointestinal System

Brush border membrane peptidases are important for completing peptide digestion into short, absorbable fractions (single amino acids, dipeptides, and tripeptides) that are taken up by enterocytes to reach the circulation. In healthy individuals, brush border enterocytes harbour numerous digestive enzymes including the majority of exopeptidases (e.g., DPP-IV and APN), most of which are membrane-bound or secreted in membrane vesicles.

6.2 Immune System (Celiac Disease Context)

In patients with CeD, gluten immunogenic peptide (GIP) exposure reactivates a CD4+ T cell-driven immunological response resulting in a broad range of gastrointestinal and systemic symptoms. Exo-peptidase supplementation is being investigated as a means of reducing the immunogenic peptide burden reaching the lamina propria, and thus modulating this immune response at its root cause.

6.3 Nutritional / Metabolic System

Degradation of dietary proteins and subsequent amino acid absorption is a key step in maintaining protein homeostasis in mammals. Adequate exopeptidase activity is thus connected to the availability of amino acids for protein synthesis, neurotransmitter production, and all other downstream metabolic functions that depend on a sufficient supply of free amino acids.

7. Dosage Forms and Dosages Reported in Studies

There is no single standardized dosage for exo-peptidase supplements, as dosing is highly dependent on the source organism, the specific enzyme type, the unit of measurement used (e.g., U/g, HUT, LAPU), and the intended indication. The following dosage information reflects what appears in the cited sources:

• Commercial aminopeptidase preparations are standardized at units such as 5000 U/g.
• In multi-enzyme supplement formulations containing exo-peptidase complexes, a typical labeled instruction is two capsules per day taken before a meal.
• In the AMYNOPEP clinical study (Frontiers in Immunology, 2024), the study was conducted with stable isotope-labelled 33-mer peptides administered to healthy volunteers under crossover conditions with and without AMYNOPEP; the precise enzyme doses administered per arm are detailed in the primary publication (DOI: 10.3389/fimmu.2024.1425982) and were designed to probe pharmacokinetics rather than establish a therapeutic dose recommendation.
• Aminogen®, a patented blend of digestive proteases from Aspergillus niger and Aspergillus oryzae, has been studied for its ability to increase in vivo absorption of whey protein concentrate, though the study focused on the multi-enzyme blend rather than a pure exo-peptidase fraction.

No government or official pharmacopeial body (NIH ODS, EFSA, WHO, EMA, or Commission E) has established a recommended daily intake or therapeutic dose range for exo-peptidase supplements.

8. Safety Considerations and Interactions

8.1 Gastric Stability

When digestive enzymes are administered exogenously, the gastric conditions in the stomach, including the highly acidic environment therein, the presence of trypsin and pepsin, and sometimes interactions with other foods or stomach contents, will result in inactivating the enzymes as a result of denaturation (i.e., a change in the enzyme's protein structure). Such denaturation reactions have negatively inhibited widespread use of digestive enzyme supplements. This is a key formulation challenge: oral exo-peptidase supplements may lose significant activity before reaching their site of action in the small intestine unless specifically formulated (e.g., enteric-coated) to survive the gastric environment.

8.2 Allergenic Potential of Fungal-Derived Enzymes

Exo-peptidases derived from fungal sources (Aspergillus niger, Aspergillus oryzae, Aspergillus fumigatus) represent proteins that could, in principle, act as allergens in sensitized individuals, a consideration applicable to all fungal enzyme ingredients in supplements. This risk is not specific to exo-peptidases but is a general property of the source organisms.

8.3 Distinction from Viral Protease Inhibitor Drug Targets

The proteases found in digestive enzyme supplements, which help digest protein in foods, are different from the viral protease (3CL) that is needed by coronaviruses to replicate and is the target of antiviral protease-inhibitor drugs such as Paxlovid.

8.4 Endogenous Enzyme Inhibition Concern

Due to possible inhibition of endogenous digestive enzymes from over-processing and rapid small intestine transit time, there are theoretical concerns that exogenous enzyme supplementation could affect the balance of endogenous proteolytic activity, though this has not been established as a clinically significant problem in published human studies.

8.5 DPP-IV and Blood Glucose

Although DPP-IV is normally secreted by cells of the intestinal brush border, supplementation with exogenous enzymes providing DPP-IV activity may complement endogenous DPP-IV and support improved protein breakdown, without adverse effects on blood sugar. This distinction is important because DPP-IV inhibitor drugs (gliptins) are used to treat type 2 diabetes, and individuals on such medications should be aware that supplemental DPP-IV enzyme activity operates by a fundamentally different mechanism (substrate hydrolysis rather than enzyme inhibition at a different molecular target).

8.6 Overall Evidence on Safety

Exopeptidases perform a critical function by systematically generating absorbable fractions, warranting future investigation as therapeutic agents. Sensitive and translational biomarkers are needed to better assess enzyme efficacy in real-meal conditions. Dedicated long-term safety studies for supplemental exo-peptidase preparations specifically are not yet available in the peer-reviewed literature; the 2024 AMYNOPEP crossover study was a short-term proof-of-concept study in healthy volunteers. The broader category of oral proteolytic enzyme supplements has a long history of use and a generally acceptable short-term safety profile in published literature, but this does not substitute for specific safety data on any particular exo-peptidase formulation.

9. Summary of Evidence Status

The biochemistry and physiology of exo-peptidases in the human digestive system is thoroughly established science. The case for their role as the final step in dietary protein digestion at the brush border is not in dispute. However, the evidence base for supplemental exo-peptidase preparations producing measurable clinical health benefits in humans remains limited:

• Protein digestion support (general): Biochemically well-supported; clinical evidence for benefit in healthy individuals is moderate at best, primarily from multi-enzyme blend studies rather than pure exo-peptidase preparations.
• Gluten peptide digestion / celiac disease: One published crossover clinical study in healthy volunteers (2024) demonstrates proof-of-concept for a specific tandem exo-peptidase combination (AMYNOPEP). Dedicated trials in celiac disease patients are not yet published. Available OTC DPP-IV and exo-peptidase products have been shown in published studies to be insufficient to degrade immunogenic gluten epitopes.
• Food technology applications: Robust industrial evidence for use in debittering, flavor development, and improving nutritional quality of fermented and hydrolyzed protein products.
• Signal transduction / peptide hormone modulation: Established physiological roles for endogenous exo-peptidases; no clinical supplementation evidence.

References

• Mourabit S, et al. "Exopeptidase combination enhances the degradation of isotopically labelled gluten immunogenic peptides in humans." Frontiers in Immunology, 2024. PMC11522800.
• Bonner ER, Tschollar W. "Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation." Alimentary Pharmacology & Therapeutics, 2025. DOI: 10.1111/apt.70014.
• ScienceDirect Topics. "Exopeptidase — an overview." Encyclopedia of Biological Chemistry (Third Edition), 2013.
• Wikipedia. "Exopeptidase." (Citing U.S. National Library of Medicine MeSH.)
• Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB). "Enzyme Nomenclature: Peptidases (EC 3.4)."
• MEROPS — The Peptidase Database. Glossary and classification.
• Stefaniak T, et al. "Characteristics of the Proteolytic Enzymes Produced by Lactic Acid Bacteria." PMC8037685.
• Tack GJ, et al. "Ineffective Degradation of Immunogenic Gluten Epitopes by Currently Available Digestive Enzyme Supplements." PMC4452362.
• Oben J, et al. "An open label study to determine the effects of an oral proteolytic enzyme system on whey protein concentrate metabolism in healthy males." PMC2500001.
• StatPearls. "Protein Intolerance." NIH/NCBI Bookshelf. NBK562306.
• Kachave R, et al. "Study of amino acids absorption and gut microbiome on consumption of pea protein blended with enzymes-probiotics supplement." PMC10844538.
• Colorado State University Hypertexts. "Small Intestinal Brush Border Enzymes."
• Yoshida H, et al. "S46 Peptidases are the First Exopeptidases to be Members of Clan PA." Scientific Reports, 2014. DOI: 10.1038/srep04977.
• Stressler T, et al. "A Novel Glutamyl (Aspartyl)-Specific Aminopeptidase A from Lactobacillus delbrueckii with Promising Properties for Application." PMC4803204.
• Ajiboye TO, et al. "Urging bioactive peptide exploration in African fermented legumes." Food Production, Processing and Nutrition, 2024. DOI: 10.1186/s43014-024-00265-1.